SciELO - Scientific Electronic Library Online

 
vol.90 número3  suppl.1Late-onset of eruptive syringomas: a diagnostic challenge índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Anais Brasileiros de Dermatologia

versão impressa ISSN 0365-0596versão On-line ISSN 1806-4841

Resumo

SILVA, Giselle de Barros et al. Vemurafenib and cutaneous adverse events - report of five cases. An. Bras. Dermatol. [online]. 2015, vol.90, n.3, suppl.1, pp.242-246. ISSN 1806-4841.  https://doi.org/10.1590/abd1806-4841.20153841.

Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.

Palavras-chave : Drug eruptions; Drug therapy; Melanoma.

        · texto em Inglês     · Inglês ( pdf )